


# **Animal Study Considerations**

**FDA Small Business  
Regulatory Education for Industry (REdI)  
Atlanta, GA  
May 9, 2017**

**Judith A. Davis, DVM, MS**  
Division of Cardiovascular Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health  
U.S. Food and Drug Administration

# Everybody Dreams of Gold



# Overview

- **Why Conduct a GLP Study?**
- **The Six Steps for a GLP Study**
- **Two Tips to Save Time, Money, & Resources**

**\$90,000 ⇒ \$1,000,000**

## **Cost of a GLP Study**



# Why Conduct a GLP Study?


- ✓ **Assures that study results are valid and accurate**
  - Requires a detailed signed/dated protocol
  - Test facility appoints a study director
  - Quality assurance ensures the study is conducted in accordance with the protocol and test facility SOPs
- ✓ **Is not an exploratory or pilot study – you should know what to expect**



# **Complete a GLP Study: 6 Steps**

- 1. Finalize and Lock Device Design**
- 2. Identify Questions of Safety**
- 3. Write the GLP Study Protocol**
- 4. Select the Test Facility**
- 5. Collect and Analyze the Data**
- 6. Write the Final Study Report**

# Step 1: Finalize/Lock Device Design



## Step 2: Identify Questions of Safety



- ✓ **Identify Safety Objectives (Risk Assessment)**
- ✓ **Will data collection require single/multiple sampling time points?**



# Step 3: Write the GLP Protocol

**Consider the following elements:**

- **Proposed IFU Statement**
  - What type(s) of data are needed?
- **Simulate Clinical Use**
  - Clinically Meaningful Study Time Points
  - Selection of the Animal Model
- **Safety Study Objectives**
  - Define Acceptability Criteria
  - Preferably Quantitative Not Qualitative

# Step 3: Write the GLP Protocol

## Proposed Acceptability Criteria

<b>Safety</b>	<p>1. XXX device must not be inferior in comparison to control device with respect to procedural complications.</p> <p>Inferior is defined as <math>\geq 5\%</math> failure rate when compared to control failure rate.</p> <p>Failure in this case is defined as clinical harm.</p>
	<p>2. XXX device must not have more bleeding events than the control device.</p> <p>A bleeding event is defined by a fall in hematocrit (HCT) of <math>\geq 20\%</math>.</p> <p>Study success is defined as the number of bleeding events with the test device is <math>\leq</math> the number of bleeding events with the control device.</p>

# Step 3: Write the GLP Protocol

## Proposed Acceptability Criteria



### Safety

1. XXX device must not be inferior in comparison to control device with respect to procedural complications.

Inferior is defined as  $\geq 5\%$  failure rate when compared to control failure rate. **Acceptable if control failure rate is defined and considered clinically acceptable.**

Failure in this case is defined as clinical harm.  
**Unacceptable as too subjective.**

2. XXX device must not have more bleeding events than the control device.

A bleeding event is defined by a fall in hematocrit (HCT) of  $\geq 20\%$ . **Acceptable if considered a clinically acceptable definition.**

Study success is defined as the number of bleeding events with the test device is  $\leq$  the number of bleeding events with the control device.

# Step 4: Test Facility Selection



## Step 4: Test Facility Selection

**This is what matters:**

- ✓ **How many similar procedures has the surgeon performed? Volume matters.**
- ✓ **Facility experience – facilities with high success rate tend to have:**
  - Experienced support staff to watch for trouble
  - Experienced support staff that can manage pain
  - The facility's infection rate: should be < 1%.

## Step 4: Test Facility Selection

# Staffing: Experience and Numbers



- ✓ **Technician number varies with model complexity**
  - Emergency/critical care background
- ✓ **Shifts**
  - Should overlap
  - Consider telemonitoring
- ✓ **Contact Information**



# Step 4: Test Facility Selection

## Cardiac Xenotransplantation: Telemonitoring and Telemetry



**Baboon Recipient Monitored Via  
Telemetry**



**Telemetry Data from the  
Baboon**

# Step 5: Collect and Analyze the Data



## ✓ How is the data collected and saved?

- What type(s) of case report forms are needed?
- Are individual animal medical records maintained in a standard, recognized format?

## ✓ Do key personnel know that they must write reports?

## ✓ Does the pathologist have access to the medical records?



# Step 6: Write the Final Study Report



- ✓ **Information specified in 21 CFR § 58.185.**
- ✓ **A Quality Assurance Unit (QAU) statement describing:**
  - Dates the study was monitored
  - Dates findings were reported
- ✓ **Reports from key personnel:**
  - In-life Veterinarian Report
  - Pathology Report

# A Poll Question



**Which of the Six Steps is most challenging for you?**

1. Finalize and Lock Device Design
2. Identify Questions of Safety
3. Write the GLP Study Protocol
4. Test Facility Selection
5. Collect and Analyze the Data
6. Write the Final Study Report

# **2 Tips to Save Time, Money, Resources**


## **1. Use the Pre-Submission Process Wisely**

## **2. Spend Money Wisely**

- **Conduct a Comprehensive Risk Assessment**
- **Conduct Exploratory Animal Studies**
- **Think “outside-the-box”**
- **Get what you pay for**

# Tip 1: Pre-Submission Process

- ✓ Seriously consider your IFU statement
- ✓ Include a meaningful draft preclinical study outline
- ✓ Ask focused questions
- ✓ Limit Supplements



# Tip 2: Spend Money Wisely

## Comprehensive Risk Assessment



- ✓ **Guide study design**
- ✓ **Consider device-related and procedural-related risks**
- ✓ **Make sure an experienced clinician is involved**

# Tip 2: Spend Money Wisely

## Conduct Exploratory Studies



- ✓ Investigate “advantages/disadvantages” of animal models
- ✓ Refine implant approach and/or overall study procedures
- ✓ Provide an estimate of “variability” of intra- and inter-animal responses
- ✓ Verify final device design before GLP studies

## **Tip 2: Spend Money Wisely**

### **Think “Outside-the-Box”**



- ✓ **Collaborate with the biocompatibility team**
- ✓ **Be cost-effective**
- ✓ **Provide your own equipment and/or expertise**

# Tip 2: Spend Money Wisely

## Did You Pay for This?



5.07.08.	Heavy breathing, discharge from mouth. No appetite. Respiration-56Bpm
	Furosemide - 40mg IM + 40mg PO
5.08.08.	Coughing, foamy discharge from mouth. E.D.U.D - normally
8 <sup>30</sup>	Furosemide - 80mg P.O
12 <sup>00</sup>	Prednisone - 20mg P.O
17 <sup>00</sup>	Furosemide - 80mg P.O
5.9.08.	Heavy abdominal breathing, agitated. Respiration 60 Bpm

5-20 - 5-26.	E.D.U.D. BAR. Lasix - 40mg P.O BID
5.27.08.	Eating, drinking, urinating and defecating - normally. Bright, alert and responsive
5.28.08.	E.D.U.D - normally. BAR
5.29.08.	E.D.U.D - normally BAR
5.30.08.	E.D.U.D - normally BAR
6.2.08.	E.D.U.D - normally BAR
6.3.08.	Pig #18 found dead @ 3 <sup>00</sup> AM



# Tip 2: Spend Money Wisely

## Did You Pay for This?



# Summary

- **Why Conduct a GLP Study?**
- **The Six Steps for a GLP Study**
- **Two Tips to Save Time, Money, & Resources**

# Questions



Please complete the session survey:  
[surveymonkey.com/r/DEV-D1S02](https://surveymonkey.com/r/DEV-D1S02)

# Call to Action

## Hallmarks of a successful GLP study include:

- Well-planned; simulates clinical use of the device per the IFU
- Safety objectives address known risks, including performance and handling of the device
- Well-documented, excellent post-procedure monitoring
- Pathology report with all high quality gross and microphotographs
- Copies of all raw data are appended to the final report

